Ir al contenido

Pharmaceutical Dosage Forms - Parenteral Medications: Volume 3: Regulations,
Foto de archivo: la portada puede ser diferente

Pharmaceutical Dosage Forms - Parenteral Medications: Volume 3: Regulations, Validation and the Future Otros -

de Sandeep Nema (Editor); John D. Ludwig (Editor)


Detalles

  • Título Pharmaceutical Dosage Forms - Parenteral Medications: Volume 3: Regulations, Validation and the Future
  • Autor Sandeep Nema (Editor); John D. Ludwig (Editor)
  • Encuadernación Otros
  • Páginas 318
  • Volúmenes 1
  • Idioma ENG
  • Editorial CRC Press
  • ISBN 9781420086485 / 1420086480
  • Dewey Decimal Code 615.19

Acerca del autor

Sandeep Nema Ph.D. is Executive Director, Pharmaceutical R&D, BioTherapeutics Pharmaceutical Sciences at Pfizer in St. Louis. Since graduating in 1992 with his doctorate, Dr. Nema has been involved with the development of small molecule and protein drugs via parenteral delivery, first at Mallinckrodt Medical and then at Pfizer (Searle, Pharmacia), and has led the formulation of four launched products. He is active in the American Association of Pharmaceutical Scientists (AAPS) and the Parenteral Drug Association (PDA), where he has chaired several meetings and focus groups. Dr. Nema holds an adjunct faculty appointment at the University of Tennessee.

John D. Ludwig Ph.D. is Vice President, Business Strategy, Operations, and Clinical Supply Planning, BioTherapeutics Pharmaceutical Sciences at Pfizer, and Site Director for the company's St. Louis Laboratories. Dr. Ludwig received a B.S. degree in Pharmacy and Ph.D. degree in Pharmaceutics from the University of Tennessee, Memphis and has held numerous research and development positions at Burroughs Wellcome Co, Searle, Inc., Pharmacia, Inc., and Pfizer. He is active in the American Association of Pharmaceutical Scientists (AAPS) and the Parenteral Drug Association (PDA) Training and Research Institute, where he has contributed to developing professional training courses and has regularly served as an instructor.